Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;11(9):1040.
doi: 10.3390/genes11091040.

OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma

Yang An  1 , Qiang Wang  1 , Fengjie Sun  1 , Guosen Zhang  1 , Fengling Wang  1 , Lu Zhang  1 , Yanan Li  1 , Weinan Ren  1 , Wan Zhu  2 , Yongqiang Li  1 , Shaoping Ji  1 , Xiangqian Guo  1
Affiliations

OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma

Yang An et al. Genes (Basel). .

Abstract

Background: Uterine carcinosarcoma (UCS) is a type of rare and aggressive tumor. The standard treatment for UCS involves surgical treatment followed by radiochemotherapy. Clinical outcomes of UCS patients are poor due to high metastasis and relapse rate. Therefore, new targeted therapy strategies for UCS are needed. Because UCS is highly heterogenous, it is critical to identify and develop prognostic biomarkers to distinguish molecular subtypes of UCS for better treatment guidance.

Methods: Using gene expression profiles and clinical follow-up data, we developed an online consensus survival analysis tool named OSucs. This web tool allows researchers to conveniently analyze the prognostic abilities of candidate genes in UCS.

Results: To test the reliability of this server, we analyzed five previously reported prognostic biomarkers, all of which showed significant prognostic impacts. In addition, ETV4 (ETS variant transcription factor 4), ANGPTL4 (Angiopoietin-like protein 4), HIST1H1C (Histone cluster 1 H1 family member c) and CTSV (Cathepsin V) showed prognostic potential in a molecular subtype-specific manner.

Conclusion: We built a platform for researchers to analyze if genes have prognostic potentials in UCS.

Keywords: gene expression profiling; molecular subtype; prognostic biomarker; survival analysis tool; uterine carcinosarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Screenshot of the main interface of OSucs at http://bioinfo.henu.edu.cn/UCS/UCSList.jsp.
Figure 2
Figure 2
Survival analysis (overall survival, OS) of clinicopathologic characteristic of uterine carcinosarcoma (UCS) patients in OSucs. (A) Histological type, (B) clinical stage, (C) hypertension, (D) therapy outcome.
Figure 3
Figure 3
Validation of previous reported prognostic biomarkers in OSucs. Kaplan-Meier plots for (A) TP53, (B) ESR1, (C) ST6GALNAC6, (D) FLT1 and (E) FLT4 (OS).
Figure 4
Figure 4
Evaluation of the prognostic value of ETV4 (ETS variant transcription factor 4) gene in OSucs. (a,c,e) Screenshots of molecular subtype selection in OSucs main interface. (b,d,f) Kaplan-Meier plots for ETV4 (OS) in All, Subtype I and Subtype II UCS, respectively.
Figure 5
Figure 5
Evaluation of the prognostic value of angiopoietin-like protein (ANGPTL4) in OSucs. Kaplan-Meier plots for ANGPTL4 in (A) All, (B) Subtype I, and (C) Subtype II UCS, respectively. p = 0 denotes p < 0.001.
Figure 6
Figure 6
Evaluation of the prognostic value of histone cluster 1 H1 family member c (HIST1H1C) in OSucs. Kaplan-Meier plots for HIST1H1C in (A) All, (B) Subtype I, and (C) Subtype II UCS, respectively.
Figure 7
Figure 7
Evaluation of the prognostic value of cathepsin V (CTSV) in OSucs. Kaplan-Meier plots for CTSV in (A) All, (B) Subtype I, and (C) Subtype II UCS, respectively. p = 0 denotes p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kanthan R., Senger J.L. Uterine carcinosarcomas (malignant mixed mullerian tumours): A review with special emphasis on the controversies in management. Obstet. Gynecol. Int. 2011;2011:470795. doi: 10.1155/2011/470795. - DOI - PMC - PubMed
    1. Matsuo K., Takazawa Y., Ross M.S., Elishaev E., Podzielinski I., Yunokawa M., Sheridan T.B., Bush S.H., Klobocista M.M., Blake E.A., et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann. Oncol. 2016;27:1257–1266. doi: 10.1093/annonc/mdw161. - DOI - PubMed
    1. Galaal K., Kew F.M., Tam K.F., Lopes A., Meirovitz M., Naik R., Godfrey K.A., Hatem M.H., Edmondson R.J. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009;143:88–92. doi: 10.1016/j.ejogrb.2008.12.014. - DOI - PubMed
    1. Thomakos N., Rodolakis A., Zagouri F., Zacharakis D., Sotiropoulou M., Akrivos N., Haidopoulos D., Papadimitriou C.A., Dimopoulos M.A., Antsaklis A. Serum CA 125, CA 15-3, CEA, and CA 19-9: A prognostic factor for uterine carcinosarcomas? Arch. Gynecol. Obstet. 2013;287:97–102. doi: 10.1007/s00404-012-2529-6. - DOI - PubMed
    1. Huang G.S., Chiu L.G., Gebb J.S., Gunter M.J., Sukumvanich P., Goldberg G.L., Einstein M.H. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol. Oncol. 2007;107:513–517. doi: 10.1016/j.ygyno.2007.08.060. - DOI - PMC - PubMed

Publication types

Substances